Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 7570516-1 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Utah Department of Health | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the Utah ePRM (electronic Pharmacotherapy Risk Management) project is to improve quality and safety of medication use while simultaneously controlling costs and detecting fraud and abuse.
The ePRM project has two objectives:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pediatric Asthmatics | Medicaid beneficiaries ≤21 years of age who meet the HEDIS criteria for persistent asthma |
| |
| Antipsychotic Therapy | Medicaid beneficiaries ≥18 years of age and enrolled ≥6 months of the past 12 months with enrollment in at least one of the past 3 months and ≥3 antipsychotic Rx within past 12 months |
| |
| Bipolar Therapy | Medicaid beneficiaries ≥18 years of age and enrolled ≥6 months of the past 12 months with enrollment in at least one of the past 3 months and a diagnosis of Bipolar in past 3 years, and ≥ 1 antidepressant Rx in past 6 months, and no mood stabilizer in past 6 months. |
| |
| Opioid Therapy | Medicaid beneficiaries ≥18 years and enrolled ≥6 of prior 12 months with enrollment in ≥1 of prior 3 months and ≥1 opioid fill in prior 3 months and none of the following in prior 12 months: Hospice CPT code or Primary diagnosis of cancer or Oncology CPT code |
| |
| Fraud and Abuse |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| provider feedback | Behavioral | The provider-level intervention includes a targeted review of trigger-flagged beneficiaries' drug utilization history and an information packet sent to providers which includes patient-specific pharmacy and medical claims history, patient specific recommendations, and provider comparative profiling. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
all medicaid recipients in the salt lake area
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jonathan R Nebeker, M.D., M.S. | VASLCHCS | Principal Investigator |
| Gary Oderda, PharmD, M.P.H. | University of Utah | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Multi-clinic site | Salt Lake City | Utah | United States |
Not provided
| ID | Term |
|---|---|
| D001249 | Asthma |
| D000092862 | Psychological Well-Being |
| D010146 | Pain |
| ID | Term |
|---|---|
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Medicaid beneficiaries who filled at least 3 opioid Rx in the last 12 months |
| Pediatric Antipsychtotic Therapy | Medicaid beneficiaries <18 years of age with at least 3 antipsychotic Rx's in the past year. |
|
| patient intervention | Behavioral | The patient intervention arm includes the provider-level intervention mentioned above in addition to Medication Therapy Management Services (MTMS), a program that provides patients one-on-one therapy counseling administered by community pharmacists who have completed an MTMS certificate program. |
|
| Process-level | Behavioral | The process-level intervention includes the provider-level intervention plus in-clinic evidence-based quality improvement workshops with opportunity for CME credit |
|
| D012130 |
| Respiratory Hypersensitivity |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
| D010549 | Personal Satisfaction |
| D001519 | Behavior |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |